Skip to Main Content

Paper Details

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
PLoS ONE
262
2019
CD45, CD45+, CD45+ cells, CD8, CD8+, CD8+ T cells, FGF, GzmB, IFN, IFN-+, Lenvatinib, PD-, PD-1, RNA, T cells, TAMs, VEGF, activated CD8+ T cells, anti-PD-1, anti-PD-1 antibody, cancer, fibroblast growth factor, genes, granzyme B, immune cell populations, interferon, interferon (IFN)-, lenvatinib, mice, mouse, programmed cell death-1, receptor tyrosine kinase, tumor, tumor-associated macrophage, tumor-associated macrophages, tumors, type-I IFN, tyrosine, vascular endothelial growth factor
Author NameAffiliation
Hiroaki KitanoThe Systems Biology Institute
  • 1 - 1

Datasets

Release 1.2